Copertina

Treatment of inflammatory bowel disease with steroid‐sparing medications is age‐dependent – Results from a Danish nationwide cohort study, 2000–2018

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Rie Louise Møller Nordestgaard, Mads Damsgaard Wewer, Mikkel Malham, Vibeke Wewer, Trine Boysen, Johan Burisch
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Paediatric‐onset immune‐mediated inflammatory disease is associated with an increased mortality risk—A nationwide study
di: Mikkel Malham, et al.
Pubblicazione: (2024)

Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood—Authors' reply
di: Mikkel Malham, et al.
Pubblicazione: (2024)

Clinical Trial: Evaluating a Single 1600 mg Tablet Regimen of 5‐Aminosalicylate for Ulcerative Colitis—The EASI Trial
di: Rie Louise Møller Nordestgaard, et al.
Pubblicazione: (2025)

Systematic review: Methotrexate—A poorly understood and underused medication in inflammatory bowel disease
di: Léa Sequier, et al.
Pubblicazione: (2024)

Research Communication: Sexual Dysfunction is a Common Early Challenge in Newly Diagnosed Inflammatory Bowel Disease
di: Mohamed Attauabi, et al.
Pubblicazione: (2025)

The contribution of dietary advanced glycation end‐products and genetic risk in the development of inflammatory bowel disease: a prospective cohort study
di: Fangyuan Jiang, et al.
Pubblicazione: (2024)

Review article: Prevention of inflammatory bowel disease—The path forward
di: Sérgio Bronze, et al.
Pubblicazione: (2024)

Editorial: GLP‐1 receptor agonists in inflammatory bowel disease—Is it time?
di: Konstantinos Arvanitakis, et al.
Pubblicazione: (2024)

Review article: Novel therapies in inflammatory bowel disease – An update for clinicians
di: Nurulamin M. Noor, et al.
Pubblicazione: (2024)

Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease
di: Tsz Hong Yiu, et al.
Pubblicazione: (2024)

Review article: Evidence‐based dietary management of inflammatory bowel disease
di: Peter R. Gibson, et al.
Pubblicazione: (2024)

Editorial: Treatments for inflammatory bowel disease across the age‐spectrum—Are they the same?
di: Agnes Hiu Yan Ho, et al.
Pubblicazione: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
di: Abhinav Vasudevan, et al.
Pubblicazione: (2024)

Letter: Allostatic load—A potential key in the development of inflammatory bowel disease
di: Maryam Kharal, et al.
Pubblicazione: (2024)

Allostatic load increases the incidence and risk of adverse prognosis in inflammatory bowel disease
di: Jianhui Zhao, et al.
Pubblicazione: (2024)

Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply
di: Abhinav Vasudevan, et al.
Pubblicazione: (2024)

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium
di: Amanda Ricciuto, et al.
Pubblicazione: (2024)

Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease
di: Thanaboon Chaemsupaphan, et al.
Pubblicazione: (2024)

Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission
di: Arta Aliu, et al.
Pubblicazione: (2024)

Letter: Light in the lumen—The expanding role of intestinal ultrasound for functional symptoms in inflammatory bowel disease
di: R. M. Mathias, et al.
Pubblicazione: (2024)

Review article: The role of the gut–brain axis in inflammatory bowel disease and its therapeutic implications
di: Christy Riggott, et al.
Pubblicazione: (2024)

Letter: Diet‐microbiome interactions in inflammatory bowel disease—Navigating towards individualised dietary strategies
di: Iris Barth, et al.
Pubblicazione: (2024)

Letter: Microbial manipulation for primary sclerosing cholangitis‐associated inflammatory bowel disease—hope on the horizon
di: D. Bogatic, et al.
Pubblicazione: (2024)

Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study
di: Carl Eriksson, et al.
Pubblicazione: (2024)

Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease?
di: Ayesha Shah, et al.
Pubblicazione: (2024)

The use of opioids nine months after surgery for Crohn's disease – a nationwide cohort study
di: Bente Mertz Nørgård, et al.
Pubblicazione: (2024)

Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease
di: Aakash Desai, et al.
Pubblicazione: (2024)

Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study
di: Kyuwon Kim, et al.
Pubblicazione: (2024)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
di: Yewan Park, et al.
Pubblicazione: (2024)

Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply
di: Vibeke Strande, et al.
Pubblicazione: (2024)

Letter: Irritable bowel syndrome and antibiotics
di: George F. Longstreth
Pubblicazione: (2024)

Inflammatory bowel disease in 2024 and beyond
di: Richard B. Gearry, et al.
Pubblicazione: (2024)

Recent steroid use and the relapse risk in ulcerative colitis patients with endoscopic healing
di: Tomohiro Fukuda, et al.
Pubblicazione: (2024)

Editorial: Mucosal healing with steroids: Once upon a time in ulcerative colitis
di: Manuel Barreiro‐de Acosta, et al.
Pubblicazione: (2024)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
di: Kyle Staller, et al.
Pubblicazione: (2024)

Performance of bowel preparation quality scales in patients with Crohn's disease
di: Virginia Solitano, et al.
Pubblicazione: (2024)

Editorial: Mucosal healing with steroids—Once upon a time in ulcerative colitis. Authors' reply
di: Tomohiro Fukuda, et al.
Pubblicazione: (2024)

Maladaptive weight control and eating behaviours in female adolescents/young adults are associated with increased risk of irritable bowel syndrome in adulthood: Results from the Growing Up Today Study (GUTS)
di: Keming Yang, et al.
Pubblicazione: (2024)

An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor‐induced liver injury
di: Mar Riveiro‐Barciela, et al.
Pubblicazione: (2024)

Drug‐induced liver injury from selective androgen receptor modulators, anabolic‐androgenic steroids and bodybuilding supplements in Australia
di: Emily Nash, et al.
Pubblicazione: (2024)